Palisade Bio (NASDAQ:PALI – Get Free Report) and Protara Therapeutics (NASDAQ:TARA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.
Profitability
This table compares Palisade Bio and Protara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palisade Bio | N/A | -148.51% | -115.16% |
| Protara Therapeutics | N/A | -55.96% | -49.06% |
Earnings and Valuation
This table compares Palisade Bio and Protara Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palisade Bio | $250,000.00 | 13.85 | -$12.30 million | ($13.98) | -0.09 |
| Protara Therapeutics | N/A | N/A | -$40.42 million | ($2.82) | -1.56 |
Institutional and Insider Ownership
11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 3.3% of Palisade Bio shares are owned by insiders. Comparatively, 12.5% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Palisade Bio has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Palisade Bio and Protara Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palisade Bio | 0 | 0 | 2 | 0 | 3.00 |
| Protara Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Palisade Bio presently has a consensus price target of $23.00, indicating a potential upside of 1,740.00%. Protara Therapeutics has a consensus price target of $22.67, indicating a potential upside of 413.98%. Given Palisade Bio’s higher possible upside, research analysts clearly believe Palisade Bio is more favorable than Protara Therapeutics.
Summary
Protara Therapeutics beats Palisade Bio on 7 of the 11 factors compared between the two stocks.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
About Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
